Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

CD137 T cell activation molecule can help identify rare antitumor T cells in human cancers

Patients with tumors that contain increased numbers of T lymphocytes generally survive longer than those with tumors without T-cell involvement, suggesting that T cells with potent antitumor function naturally exist in cancer and control tumor progression. With the exception of melanoma, it has been difficult to identify and isolate the tumor-reactive T cells from common cancers, however, the ability to do so could be used to fight a patient's own cancer.

14 Nov 2013

Johns Hopkins students take the top honor for developing PrestoPatch system

A Johns Hopkins undergraduate biomedical engineering student team that devised a two-part system to improve the way life-saving shocks are delivered to hearts earned first-prize in the undergraduate division of a national Collegiate Inventors Competition. In the graduate-level competition, Isaac Kinde, a Johns Hopkins medical student, received third-place honors for developing a test to detect ovarian and endometrial cancers as part of a team at the Johns Hopkins Kimmel Cancer Center.

14 Nov 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

New report explains occurrence of breast cancer in women with normal BRCA genes

Since 1994, many thousands of women with breast cancer from families severely affected with the disease have been tested for inherited mutations in BRCA1 and BRCA2. The vast majority of those patients were told that their gene sequences were normal.

25 Oct 2013

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

An investigational new PARP inhibitor, BMN 673, is showing early responses in patients with heavily pretreated, advanced, BRCA-related cancers of the breast and ovary, according to phase I clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

23 Oct 2013

BRCA1/2 mutations may alter endometrial, ovarian function

Scientists have detected significant differences in endometrial thickness and hormone levels in women with and without BRCA1/2 mutations that may play a role in cancer susceptibility or development.

22 Oct 2013

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

AstraZeneca today announced the first patient randomized in a Phase 3 clinical trial for selumetinib, an oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer whose tumors are KRAS mutation-positive.

22 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).

21 Oct 2013

New investigational drug offers potential treatment option for lung cancer

PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

21 Oct 2013

Women diagnosed with breast cancer are 39% more likely to develop second cancer

Women diagnosed with invasive breast cancer are 39% more likely to develop a second cancer in a different part of the body. Such is the conclusion of a recent study, pioneered by female Spanish researchers.

18 Oct 2013

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State University report in a new study.

18 Oct 2013

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments.

17 Oct 2013

Researchers discover why women with BRCA gene develop breast and ovarian cancer

Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.

17 Oct 2013

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology.

15 Oct 2013

PARP inhibitor drugs and chemotherapy can help women with ovarian cancer live longer

Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.

13 Oct 2013

Cedars-Sinai woman researcher puts extensive effort to increase awareness on ovarian cancer research

Julie Miller is a key part of an extensive effort at Cedars-Sinai to increase awareness of and support for women's cancer research. She not only has registered to participate in clinical research, but she's also lacing up her running shoes.

11 Oct 2013

Next-generation sequencing technology effective for detecting BRCA1 and BRCA2 mutations

The recognition of a causal link between mutations in BRCA1 and BRCA2 genes and increased risk of developing breast and ovarian cancer has intensified the demand for genetic testing. Identifying mutations in these large genes by conventional methods can be time consuming and costly.

9 Oct 2013

Women with recurrent ovarian cancer survive longer after treatment with cediranib

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress.

30 Sep 2013

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

CD137 T cell activation molecule can help identify rare antitumor T cells in human cancers

Johns Hopkins students take the top honor for developing PrestoPatch system

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

New report explains occurrence of breast cancer in women with normal BRCA genes

New PARP inhibitor shows early responses in patients with advanced BRCA-related cancers

BRCA1/2 mutations may alter endometrial, ovarian function

AstraZeneca begins selumetinib Phase 3 clinical trial in NSCLC patients

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

New investigational drug offers potential treatment option for lung cancer

Women diagnosed with breast cancer are 39% more likely to develop second cancer

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

Scientists identify 127 mutated genes that appear to drive development of tumors in the body

Researchers discover why women with BRCA gene develop breast and ovarian cancer

Results announced for Phase II PRECEDENT trial of vintafolide for treatment of platinum-resistant ovarian cancer

PARP inhibitor drugs and chemotherapy can help women with ovarian cancer live longer

Cedars-Sinai woman researcher puts extensive effort to increase awareness on ovarian cancer research

Next-generation sequencing technology effective for detecting BRCA1 and BRCA2 mutations

Women with recurrent ovarian cancer survive longer after treatment with cediranib

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in